Verkman Alan S, Esteva-Font Cristina, Cil Onur, Anderson Marc O, Li Fei, Li Min, Lei Tianluo, Ren Huiwen, Yang Baoxue
Departments of Medicine and Physiology, University of California, San Francisco, CA, 94143-0521, USA,
Subcell Biochem. 2014;73:165-77. doi: 10.1007/978-94-017-9343-8_11.
Urea transporter (UT) proteins, which include isoforms of UT-A in kidney tubule epithelia and UT-B in vasa recta endothelia and erythrocytes, facilitate urinary concentrating function. Inhibitors of urea transporter function have potential clinical applications as sodium-sparing diuretics, or 'urearetics,' in edema from different etiologies, such as congestive heart failure and cirrhosis, as well as in syndrome of inappropriate antidiuretic hormone (SIADH). High-throughput screening of drug-like small molecules has identified UT-A and UT-B inhibitors with nanomolar potency. Inhibitors have been identified with different UT-A versus UT-B selectivity profiles and putative binding sites on UT proteins. Studies in rodent models support the utility of UT inhibitors in reducing urinary concentration, though testing in clinically relevant animal models of edema has not yet been done.
尿素转运蛋白(UT)包括肾小管上皮细胞中的UT-A异构体以及直小血管内皮细胞和红细胞中的UT-B异构体,它们有助于尿液浓缩功能。尿素转运蛋白功能抑制剂作为保钠利尿剂或“尿素利尿剂”,在不同病因引起的水肿(如充血性心力衰竭和肝硬化)以及抗利尿激素分泌失调综合征(SIADH)中具有潜在的临床应用价值。对类药物小分子进行的高通量筛选已鉴定出具有纳摩尔效力的UT-A和UT-B抑制剂。已鉴定出具有不同UT-A与UT-B选择性谱以及UT蛋白上推定结合位点的抑制剂。在啮齿动物模型中的研究支持UT抑制剂在降低尿液浓缩方面的效用,不过尚未在临床上相关的水肿动物模型中进行测试。